Novartis pipeline setback: pelacarsen failure pressures premium valuation

What happened

Novartis shares fell 3.3% on Monday after its cholesterol-lowering candidate pelacarsen failed a closely watched Phase III outcomes study, removing a key non-oncology pipeline catalyst that had been expected to validate the company's premium multiple. The failure casts doubt on the Lp(a)-lowering mechanism as a cardiovascular intervention and raises the stakes for other H2 2026 readouts, including remibrutinib in relapsing MS, del-desiran in myotonic dystrophy, and Pluvicto's label expansion. This setback directly challenges the market narrative that Novartis could rely on late-stage pipeline success to offset the ongoing Entresto patent cliff, which already pressured H1 2026 results with a 2% constant-currency sales decline and 230 bps margin compression. While Novartis retains balance-sheet strength and strong commercial momentum in growth brands like Kisqali, Kesimpta, and Pluvicto, the failure removes one of the few large-scale revenue opportunities that could have justified the stock's 23x earnings multiple over the next 12-18 months. Investors should now recalibrate expectations toward a lower probability of the bull case, with the stock likely to drift toward the lower end of the prior $128-$178 scenario range unless other catalysts deliver positive surprises.

Implication

The failed pelacarsen study materially reduces the probability of the bull case, which relied on two successful H2 2026 readouts to support a move above $170. With one major catalyst eliminated, the burden now falls almost entirely on remibrutinib, del-desiran, and Pluvicto to rescue the pipeline story, and any further disappointments could push the stock toward the bear case value of $128. Current valuation at around $147 (post-decline) still embeds substantial pipeline optimism, leaving little margin of safety for investors. We now see the attractive entry as potentially below $140, and would avoid averaging down until there is evidence that group constant-currency sales have turned positive or another major catalyst has succeeded. For existing holders, the risk/reward has worsened, and trimming positions on any short-term rebound toward $155-$160 may be prudent given the reduced upside asymmetry.

Thesis delta

The prior thesis of waiting for pipeline validation to justify the premium multiple has weakened because one of the two expected positive readouts has now failed. Pelacarsen's failure shifts the probability weight from the bull scenario toward the bear scenario, suggesting the stock's fair value is likely closer to $140 than $158. We maintain a WAIT rating but lower conviction from 4 to 3 and adjust the attractive entry to below $140, while monitoring remaining catalysts for any offsetting positive development.